Antiangiogenic therapy in myelodysplastic syndromes: Is there a role?

Keyphrases

• 5-azacytidine 16%
• 5q-syndrome 16%
• Angiogenesis 33%
• Angiogenesis Inhibition 16%
• Angiogenesis Inhibitors 16%
• Angiogenic 16%
• Anti-angiogenesis 16%
• Antiangiogenic Activity 16%
• Antiangiogenic Therapy 100%
• Clinical Evaluation 16%
• Decitabine 16%
• Hematological Malignancies 16%
• Hypomethylating Agents 16%
• Immunosuppressive Agents 16%
• In Vitro Research 16%
• Lenalidomide 33%
• Metastasis 16%
• Multi-targeted Tyrosine Kinase Inhibitors 16%
• Multiple Mechanisms of Action 16%
• Myelodysplastic Syndrome 100%
• Preclinical Evaluation 16%
• Solid Tumor Therapy 16%
• Solid Tumors 16%
• Thalidomide 16%
• Translational Research 16%
• U.S. Food 16%
• Vascular Endothelial Growth Factor 16%

Pharmacology, Toxicology and Pharmaceutical Science

• 5q- Syndrome 16%
• Angiogenesis Inhibitor 16%
• Antiangiogenic 16%
• Antiangiogenic Therapy 100%
• Azacitidine 16%
• Clinical Trial 16%
• Decitabine 16%
• Hematologic Malignancy 16%
• Lenalidomide 33%
• Myelodysplastic Syndrome 100%
• Protein Tyrosine Kinase Inhibitor 16%
• Solid Malignant Neoplasm 33%
• Thalidomide 16%
• Vasculotropin 16%